Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233820443> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4233820443 endingPage "8160" @default.
- W4233820443 startingPage "8160" @default.
- W4233820443 abstract "8160 Background: In the next 2 decades, 70% of all cancers will occur in elderly patients (pts) above 70 . Methods : In Gerico-01, with pts 70 years or older, the primary endpoint of the study was the autonomy preservation as measured by the ADL in 6 item; 2nd objectives were toxicity (NCI-CTC v2), PK study of V, the serum PSA or CA 15–3 levels variation and the tumor targets evaluation (RECIST); the primary tumors were either metastatic disease from a primary Breast, or a lung or a prostate Ca. The treatment was Q-3 weeks an oral combination chemotherapy (CT) with C day 1–14 at a starting dose of 750 mg/m2 twice a day and oral V, days 1 and 8 at a starting dose of 45 mg/m2/d. After three cycles the dose could be escalated up to 1000 mg/m2 twice a day and 60 mg/m2 respectively. At inclusion, the creatinin clearance must be above 30 ml/min (Cokroft Formula). Dose adaptation was according to the observed toxicity. C+V was discontinued in progressive disease, or the loss of 2 or more ADL criteria, or any grade III-IV toxicities. Results : Between december 2002 and 2003, 65 pts were included in 8 different French centers and 12 are still under treatment. The pts' median age was 75 yrs (70–86); the primary was a breast in 28, a prostate in 31 and a lung Ca in 6 pts. ADL preservation/ improvement was seen in 22 evaluated pts at 6 cycles and decreased in 6 pts. Among breast carcinoma there were 5 partial remission, 1 in prostate and 1 in lung ca, stable disease was seen in 2 breast, 9 prostate, 1 lung; C+V was stopped in 9 progressive disease, 3 cases of toxicity, 1 pt. refusal. Among 15 Severe Adverse Events, 1 hand-foot syndroma, 2 overdosages, 1 occlusion, 1 femoral neck fracture and 1 tachycardia. Conclusion : Although response rate remains limited, this oral C+V regimen is very well tolerated in elderly pts in preserving their ADL and a good quality of life for pts with uncurable disease. No significant financial relationships to disclose." @default.
- W4233820443 created "2022-05-12" @default.
- W4233820443 creator A5032655584 @default.
- W4233820443 creator A5035921332 @default.
- W4233820443 creator A5043043596 @default.
- W4233820443 creator A5044093448 @default.
- W4233820443 creator A5045636071 @default.
- W4233820443 creator A5065307357 @default.
- W4233820443 creator A5073676617 @default.
- W4233820443 creator A5079840874 @default.
- W4233820443 creator A5082132479 @default.
- W4233820443 date "2004-07-15" @default.
- W4233820443 modified "2023-09-30" @default.
- W4233820443 title "Preservation of Activities Daily Living (ADL) in a phase-II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: The GERICO-01 Study by the French FNCLCC Group" @default.
- W4233820443 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.8160" @default.
- W4233820443 hasPublicationYear "2004" @default.
- W4233820443 type Work @default.
- W4233820443 citedByCount "0" @default.
- W4233820443 crossrefType "journal-article" @default.
- W4233820443 hasAuthorship W4233820443A5032655584 @default.
- W4233820443 hasAuthorship W4233820443A5035921332 @default.
- W4233820443 hasAuthorship W4233820443A5043043596 @default.
- W4233820443 hasAuthorship W4233820443A5044093448 @default.
- W4233820443 hasAuthorship W4233820443A5045636071 @default.
- W4233820443 hasAuthorship W4233820443A5065307357 @default.
- W4233820443 hasAuthorship W4233820443A5073676617 @default.
- W4233820443 hasAuthorship W4233820443A5079840874 @default.
- W4233820443 hasAuthorship W4233820443A5082132479 @default.
- W4233820443 hasConcept C121608353 @default.
- W4233820443 hasConcept C126322002 @default.
- W4233820443 hasConcept C126894567 @default.
- W4233820443 hasConcept C203092338 @default.
- W4233820443 hasConcept C2775930923 @default.
- W4233820443 hasConcept C2776694085 @default.
- W4233820443 hasConcept C2776907518 @default.
- W4233820443 hasConcept C2777511904 @default.
- W4233820443 hasConcept C2777909004 @default.
- W4233820443 hasConcept C2778239845 @default.
- W4233820443 hasConcept C2778822529 @default.
- W4233820443 hasConcept C2780192828 @default.
- W4233820443 hasConcept C2780350996 @default.
- W4233820443 hasConcept C29730261 @default.
- W4233820443 hasConcept C526805850 @default.
- W4233820443 hasConcept C530470458 @default.
- W4233820443 hasConcept C535046627 @default.
- W4233820443 hasConcept C71924100 @default.
- W4233820443 hasConcept C90924648 @default.
- W4233820443 hasConceptScore W4233820443C121608353 @default.
- W4233820443 hasConceptScore W4233820443C126322002 @default.
- W4233820443 hasConceptScore W4233820443C126894567 @default.
- W4233820443 hasConceptScore W4233820443C203092338 @default.
- W4233820443 hasConceptScore W4233820443C2775930923 @default.
- W4233820443 hasConceptScore W4233820443C2776694085 @default.
- W4233820443 hasConceptScore W4233820443C2776907518 @default.
- W4233820443 hasConceptScore W4233820443C2777511904 @default.
- W4233820443 hasConceptScore W4233820443C2777909004 @default.
- W4233820443 hasConceptScore W4233820443C2778239845 @default.
- W4233820443 hasConceptScore W4233820443C2778822529 @default.
- W4233820443 hasConceptScore W4233820443C2780192828 @default.
- W4233820443 hasConceptScore W4233820443C2780350996 @default.
- W4233820443 hasConceptScore W4233820443C29730261 @default.
- W4233820443 hasConceptScore W4233820443C526805850 @default.
- W4233820443 hasConceptScore W4233820443C530470458 @default.
- W4233820443 hasConceptScore W4233820443C535046627 @default.
- W4233820443 hasConceptScore W4233820443C71924100 @default.
- W4233820443 hasConceptScore W4233820443C90924648 @default.
- W4233820443 hasIssue "14_suppl" @default.
- W4233820443 hasLocation W42338204431 @default.
- W4233820443 hasOpenAccess W4233820443 @default.
- W4233820443 hasPrimaryLocation W42338204431 @default.
- W4233820443 hasRelatedWork W1942209073 @default.
- W4233820443 hasRelatedWork W1995504689 @default.
- W4233820443 hasRelatedWork W1999778859 @default.
- W4233820443 hasRelatedWork W2039980848 @default.
- W4233820443 hasRelatedWork W2125930061 @default.
- W4233820443 hasRelatedWork W2287561065 @default.
- W4233820443 hasRelatedWork W2291375065 @default.
- W4233820443 hasRelatedWork W2387856323 @default.
- W4233820443 hasRelatedWork W2590140540 @default.
- W4233820443 hasRelatedWork W4233820443 @default.
- W4233820443 hasVolume "22" @default.
- W4233820443 isParatext "false" @default.
- W4233820443 isRetracted "false" @default.
- W4233820443 workType "article" @default.